A drug capable of regenerating spinal cord cells has opened the door to reverse states of quadriplegia, according to preliminary results of a clinical study in 48 humans tested, of which a 66% with cervical lesions increased from the total loss of movement to the recovery of motor skills.
scientist Michael Fehlings presented Canada's first trial, based on the use of the protein B-210, created at the University of Montreal for the pharmaceutical Bioaxone and marketed as 'Cethrin' in the scientific conference for the Global Spine Congress column held in Barcelona.
The study, conducted at eight research centers in U.S. and Canada, show results "really encouraging" to radically change the therapy for people who are paralyzed as a result of car accidents or sports injuries, explains neuroscientist Fehlings to Europa Press.
palsy specialist with more than 300 scientific papers published, explained that the drug used in the trial, whose results were published in the coming months in the Journal of Neurotrauma ', has a protein manufactured by recombinant DNA technology.
is a protein that blocks a molecule called Rho and prevents bone marrow cells, destroyed or seriously injured in a trauma, can regenerate.
In the experiment, we used a single dose of the drug was injected during surgery for bone regeneration, and continued the evolution of the patient for one year, all between 2005 and 2007.
For example, the coordinator of the trial showed the video of a patient with severe paralysis could not move my arms and hands and could not sustain itself in any position.
"After a year, he regained use of his hands, could move in a chair and had begun to walk with the aid of a structure." The affectations
chest, there was a low level of regeneration, explained, however, in the neck were quite significant levels of improvement.
The trial, phase I / IIa, verified the safety and feasibility of therapy, and the next step will be randomized to control group and a protocol rigorous blind assessment.
"We have seen that the drug is safe and feasible, and this is very encouraging because it is the first time that a recombinant is used to promote growth of nerve fibers. Now we have to find that actually works for a large number of patients, "Fehlings found. Europa Press
Barcelona 03/28/2011
0 comments:
Post a Comment